Caricamento...
New developments in the management of severe skin and deep skin structure infections – focus on tedizolid
Tedizolid, a novel oxazolidinone, is approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs). Tedizolid offers several potential advantages over current ABSSSI treatment options. First, tedizolid has a prolonged half-life, which allows for once-daily dosing. Second, te...
Salvato in:
| Pubblicato in: | Ther Clin Risk Manag |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4447168/ https://ncbi.nlm.nih.gov/pubmed/26045667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S64553 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|